| 3-Dimensional Pharmaceuticals (Exton, PA, USA) | Structure-based drug design | http://www.jnj.com
Acquired by Johnson & Johnson, January 2003, for $88 million | 1993 |
| |
| 7TM Pharma (Copenhagen, Denmark) | Focus on GPCR targets, including computational structure prediction | http://www.7tm.com | 2000 |
| |
| Affinium Pharmaceuticals (Toronto, ON, Canada) | Structure solution and homology analysis | http://afnm.com
Founded as Integrative Proteomics, from the merger of Chalon Biotech and Borealis Biosciences. Changed name in February 2002. | 2000 |
| |
| AlgoNomics (Ghent, Belgium) | Rationally designed vaccines based on structural genomic data. | http://www.algonomics.com | 1999 |
| |
| Astex Technology (Cambridge, UK) | High-throughput X-ray crystallography to guide 'fragment' best lead discovery | http://www.astex-technology.com | 1999 |
| |
| BioCryst Pharmaceuticals (Birmingham, AL, USA); NASDAQ: BCRX | Structure-based drug design, focused on PNP inhibitors | http://www.biocryst.com | 1986 |
| |
| Cengent Therapeutics (San Diego, CA, USA) | Structure-based drug design and contract crystallography | http://www.cengent.com
A merger of Structural Bioinformatics and Geneformatics in January 2003. (Geneformatics previously acquired Structure Function Genomics LLC; Structural Bioinformatics had acquired some assets of Molecular Applications Group.) | 1997 |
| |
| Concurrent Pharmaceuticals (Fort Washington, PA, USA) | De novo drug design and computational screening | http://www.concurrentpharma.com | 2001 |
| |
| Crystal Genomics (Taejon, Korea) | High-throughput structure solution, X-ray and NMR | http://crystalgenomics.com | 2000 |
| |
| deCode Genetics (Reykjavik, Iceland); NASDAQ: DCGN | Structure solution via Emerald BioStructures group | http://www.emeraldbiostructures.com
DeCode acquired MediChem Life Sciences in March 2002, which in turn had acquired Emerald BioStructures in May 2000. The structures group is in Bainbridge Island, WA, USA. | 1997 |
| |
| Pintex Pharmaceuticals (Watertown, MA, USA) | Structure-based design around the Pin1 enzyme | http://www.pintexpharm.com | 1999 |
| |
| Predix Pharmaceuticals (Ramat Gan, Israel) | De novo prediction of three-dimensional structure of G-coupled protein receptors | http://www.predixpharm.com
Founded as BioIT; merged with Physiome Sciences in August 2003 | 2000 |
| |
| Rib-X Pharmaceuticals (New Haven, CT, USA) | Focus on ribosomal crystallography for novel anti-infectives | http://www.rib-x.com | 2001 |
| |
| Structural GenomiX (San Diego, CA, USA) | High-throughput 3-dimensional protein structure solution | http://www.stromix.com
Acquired Prospect Genomics | 1999 |
| |
| Syrrx (San Diego, CA, USA) | High-throughput crystal structure solution | http://www.syrrx.com | 2000 |
| |
| TRIAD Therapeutics (San Diego, CA, USA) | NMR systems to build focused compound libraries | http://www.triadtherapeutics.com | 1998 |
| |
| Vertex Pharmaceuticals (Cambridge, MA, USA); NASDAQ: VRTX | 'Rational drug design,' including structure solution | http://www.vpharm.com | 1989 |
| |
| Xencor (Monrovia, CA) | Structure-based protein engineering | http://www.xencor.com | 1997 |
